Address
MPM Capital
601 Gateway Boulevard
Suite 350
South San Francisco, CA 94080
United States
Phone
Email
Website
Recent investment activity
KANDO id: 30789
Relation
Renamed to
Funding rounds
Investment activity status
Active investor
Selected investments
Displaying 51 - 71 of 71| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Acorda Therapeutics Inc | A biotechnology company whose mission is to develop and market therapeutic products for spinal cord injury and other central nervous system disorders. | N/A | |||
|
|
Adolor Corp | N/A | ||||
|
|
Alnara Pharmaceuticals Inc | N/A | ||||
|
|
ARYx Therapeutics Inc | N/A Initial investment | ||||
|
|
AVEO Pharmaceuticals Inc | Biopharmaceutical company discovering, developing and commercializing cancer therapeutics. | N/A Initial investment | |||
|
|
BioMarin Pharmaceutical Inc | N/A | ||||
|
|
Elixir Pharmaceuticals Inc | Series C Initial investment | ||||
|
|
EndoGastric Solutions Inc | Series E | ||||
|
|
EndoGastric Solutions Inc | Venture | ||||
|
|
EndoGastric Solutions Inc | Series B | ||||
|
|
EndoGastric Solutions Inc | Series A | ||||
|
|
Epizyme Inc | Focusing on the discovery and development of innovative drugs targeting epigenetic enzymes, in particular histone methyltransferases (HMTs). | Series B | |||
|
|
Keryx Biopharmaceuticals Inc | N/A | ||||
|
|
MacroGenics Inc | Biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases. | Series C | |||
|
Nanosys Inc | Nanotechnology-enabled systems | N/A | |||
|
|
NeoVista Inc | Series E Follow-on investment | ||||
|
|
NeoVista Inc | Series D Follow-on investment | ||||
|
|
NeoVista Inc | Series C Initial investment | ||||
|
|
Portola Pharmaceuticals Inc | N/A | ||||
|
|
Rinat Neuroscience Corp | Discovers and commercializes novel antibody based drugs and drug targets for the major mental and neuro-degenerative diseases | Series B Initial investment |
| Company | Profile | Funding | ||
|---|---|---|---|---|
|
|
CODA Biotherapeutics | N/A Initial investment Exited Write-off |